Back to search
FDAFDA · Food and drugs·Recall number D-0016-2027

IMAAVY (nipocalimab-aahu) Injection, 300 mg /1.62 mL (185 mg/mL) per single-dose vial, For Intravenous Infusion After Dilution, Rx only, Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044. NDC: 57894-800-01

Published October 14, 2026 · Recall initiated: September 23, 2026

Summary

FDA records drug Class II recall D-0016-2027, published October 14, 2026 and initiated September 23, 2026. Recalling firm: J&J INNOVATIVE MEDICINE; Status: Ongoing; Reported quantity: 49 vials; Lot: Lot JNYJ1208; Exp. 10/30/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of particulate matter.

What to do

Voluntary: Firm initiated · Letter

Get an email if IMAAVY has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
IMAAVY
Manufacturer
J&J INNOVATIVE MEDICINE
Distributor
OH
Lot
Lot JNYJ1208; Exp. 10/30/2027
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was IMAAVY (nipocalimab-aahu) Injection, 300 mg /1.62 mL (185 mg/mL) per single-dose vial, For Intravenous Infusion After Dilution, Rx only, Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044. NDC: 57894-800-01 recalled?

Yes. FDA published recall D-0016-2027 on October 14, 2026. Reported hazard: Presence of particulate matter.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: IMAAVY.